Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
durvalumab (imfinzi) (1 trial)
gefitinib (iressa) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Trials (1 total)
Trial APIs (2 total)